Obesity and Drug Dosing: Clinical Pharmacology Considerations; Request for Comments
FDA-2026-N-3499-0001Notice
Comments
16
Last activity Jun 30, 2026
Deadline
Closed on Jul 1, 2026
Closed Jul 1, 2026
Net supportiSupport minus oppose · campaigns included
+100%
+100% excluding campaigns
Document
Details
The document's own metadata, straight from the source system.
- Title
- Obesity and Drug Dosing: Clinical Pharmacology Considerations; Request for Comments
- Posted
- May 1, 2026
- Comment period
- May 1, 2026 – Jul 1, 2026
- FR Doc
- 2026-08521
- Topics
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Include campaigns
Analyzed 3 of 16 comments
19%· analysis in progress
Stance breakdown
+100%
Net support
Support3Not yet analyzed13
Aggregates include form-letter campaigns. Excluding them, net support is +100% across organic comments.
Who commented
Breakdown by commenter type.
Individual
2
Academic
1
Not yet analyzed
13
Comments over time
Weekly arrivals, stacked by stance.
Posted May 1, 2026Deadline Jul 1, 2026
Apr 27May 4Jun 15Jun 22Jun 29
Support3Oppose0Other0
Support × commenter type
How each type splits across stance.
Support
Oppose
Other
Individual
100%
0%
0%
Academic
100%
0%
0%
Issues raised
The docket's canonical issues. Select one to browse its comments.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
Filter:
- Jun 30, 2026Comment from Novo NordiskAnalysis pending📎 AttachmentRead comment →
- Jun 30, 2026Comment from The Obesity SocietyAnalysis pending📎 AttachmentRead comment →
- Jun 30, 2026Comment from Bristol Myers SquibbAnalysis pending📎 AttachmentRead comment →
- Jun 30, 2026Comment from NovartisAnalysis pending📎 AttachmentRead comment →
- Jun 30, 2026Comment from International Consortium for Innovation and Quality in Pharmaceutical Development (IQ Consortium)Analysis pending📎 AttachmentRead comment →
- Jun 30, 2026Comment from CertaraAnalysis pending📎 AttachmentRead comment →
- Jun 30, 2026Comment from GSKAnalysis pending📎 AttachmentRead comment →
- Jun 29, 2026Comment from William ZamboniSupportAcademic
William C. Zamboni, a researcher at UPMC Hillman Cancer Center, supports the need for further study on how body size and composition affect the clearance of complex drugs like biologics. He argues that current weight-based dosing may lead to under-dosing in obese patients and calls for the development of new metrics and biomarkers to optimize dosing.
Read comment → - Jun 29, 2026Comment from American Academy of PediatricsAnalysis pending📎 AttachmentRead comment →
- Jun 26, 2026Comment from Celerion, Inc.Analysis pending📎 AttachmentRead comment →